Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.

DNA Alkylator^[1]

Carboplatin is an antitumor agent, with an increased DNA-binding activity in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts^[1]. Carboplatin is less cytotoxic to human ovarian cells such as A2780, SKOV3, IGROV1 and HX62 than 17-AAG, with IC₅₀s of 6.177, 12.442, 2.233 and 116.068 μM, respectively. Moreover, Carboplatin does not affect HSP90 or change the activity of 17-AAG to inhibit HSP90^[2]. Carboplatin reduces the viability of Brca1 (IC₅₀, 3.4 μM) and Brca2 cells (IC₅₀, 1.9 μM). Carboplatin (25 μM) combined with ABT-888 also shows an apoptotic effect in BRCA1 cells^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Carboplatin (60 mg/kg, i.p.) shows a modest effect on the tumor, but significantly inhibits tumor growth in combination with 17-AAG in mice bearing A2780 human ovarian cancer xenografts^[2]. Carboplatin (25 mg/kg, p.o.) combined with ABT-888 delays tumor growth in Brca2 xenografts^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

371.25

C₆H₁₂N₂O₄Pt

41575-94-4

卡铂；碳铂

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

H₂O : 13.89 mg/mL (37.41 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Carboplatin’s activity)

DMF : 1 mg/mL (2.69 mM; Need ultrasonic; DMSO can inactivate Carboplatin’s activity)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

• 1.

  Carboplatin is resuspended in N-Methyl-2-pyrrolidone (NMP) to create a stock solution and diluted in PTD buffer (30 % PEG-400; 5 % Tween 80; 65 % Dextrose water, D5W)^[4].

• [1]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9.

  [2]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78.

  [3]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther. 2012 Sep;11(9):1948-58.

  [4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.

Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying the effect of sequence of exposure to 17-AAG or Carboplatin, cells are exposed to increasing concentrations of 17-AAG or Carboplatin for 24 h. A period of 24-h exposure to the first agent is chosen so that the A2780 cells will be exposed to the first drug for at least one doubling time (18-24 h). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 h) or medium is added for 96 h. SRB assays are carried out. All experiments are carried out in triplicate^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Mice^[2]
The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) by injecting 4 × 10⁶ cells in each flank. Mice with established tumors corresponding to a mean volume of 0.69 mm³ are randomized into groups (six animals each) for treatment with either control vehicle (43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water) days 1-4, 17-AAG (80 mg/kg intraperitonially, days 1-4), Carboplatin (60 mg/kg IP day 0) or a combination of 17-AAG (80 mg/kg IP days 1-4) and Carboplatin (60 mg/kg IP day 0). Tumor growth is assessed three times weekly and tumor volumes are calculated according to a validated formula: volume = 4.19 × (a/4 + b/4)³, where a is the longer and b the shorter diameter. Tumor volumes are then expressed as a proportion of the volume at the start of treatment (relative tumor volume)^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9.

  [2]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78.

  [3]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther. 2012 Sep;11(9):1948-58.

  [4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.